A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas.
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Jul 2016 Status changed from active, no longer recruiting to completed.
- 30 Jan 2013 Planned end date changed from 1 Jun 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.